Ruptured mycotic aneurysms: Report and outcomes of two surgically managed patients

Endovascular treatment of mycotic aneurysms: An update meta-analysis

INTRODUCTION

Intracranial mycotic or infectious aneurysms result from the infection of arterial walls, most caused by bacterial or fungal organisms. These infections can weaken the arterial wall, leading to the formation of an aneurysm, a localized dilation, or a bulge. The management can be conservative mainly based on antibiotics or invasive methods such as clipping or endovascular treatment.

PURPOSE

We performed a systematic review and meta-analysis of the current literature on endovascular treatment of mycotic aneurysms, analyzing the safety and efficacy associated with this procedure.

METHODS

We systematically searched on PUBMED, Cochrane Library, Embase, and Web of Science databases. Our search strategy was carefully crafted to conduct a thorough investigation of the topic, utilizing a comprehensive combination of relevant keywords. This meta-analysis included all studies that reported endovascular treatment of mycotic aneurysms. To minimize the risk of bias, studies with fewer than four patients, studies where the main outcome was not found, and studies with no clear differentiation between microsurgical and endovascular treatment were excluded.

RESULTS

In a comprehensive analysis of 134 patients, it was observed that all except one patient received antibiotics as part of their treatment. Among the patients, 56% (a total of 51 out of 90 patients) underwent cardiac surgery. Additionally, three patients required a craniotomy following endovascular treatment. 12 patients experienced morbidity related to the procedures performed, indicating complications arising from the interventions. Furthermore, four aneurysms experienced rebleeding while treatment. A pooled analysis of the endovascular treatment of the mycotic aneurysm revealed a good level of technical success, achieving a 100% success rate in 12 out of 14 studies (97-100%; CI 95%; I2 = 0%), as illustrated in Fig. 2. Similarly, the aneurysm occlusion rate demonstrated a notable efficacy, with a success rate of 97% observed in 12 out of 14 studies (97-100%; CI 95%; I2 = 0%), as depicted in Fig. 3.

CONCLUSION

The results strongly support the efficacy of endovascular treatment in achieving technical success, complete aneurysm occlusion, and favorable neurological outcomes. Additionally, the notably low incidence of complications and procedure-related mortality reaffirms the safety and benefits associated with this intervention.

[Therapeutic and endovascular management of cerebral mycotic aneurysms]

Infective endocardites are associated with both ischemic and hemorrhagic neurological complications and also with cerebral abscesses and the development of "mycotic" aneurysms, which are detected in about 5 % of patients in the acute and sub-acute phase of the infection. Data about their natural history and their hemorrhagic risk are scarce and fragmented. The therapeutic management is represented by the medical treatment of the infection with interventional abstention, the surgical treatment and the endovascular approach by selective embolization of the aneurysm. No evidence is provided concerning the superiority of a specific approach. Mycotic aneurysms remain a diagnostic and therapeutic challenge and their management is necessarily based on a multidiscplinary approach.

A Rare Case of Serratia marcescens Causing Mycotic Aneurysm and Septic Emboli in Intravenous Drug User

There are few literatures highlighting the presence of a mycotic aneurysm in the setting of bloodstream infection by Serratia. A 33-year-old male with a history of Marfan syndrome, mitral valve prolapse, and intravenous drug use (IVDU) presented to the ED with fever, nausea, and non-bloody emesis, and vague abdominal pain with concern for sepsis. With the strong association between IVDU and infective endocarditis, transthoracic and transesophageal echocardiograms were performed and were negative for vegetations. Abdominal CT and positron emission tomography (PET) scan were performed and revealed thrombosis at the first jejunal branch of the superior mesenteric artery (SMA), left renal pole infarct, and superior splenic pole infarct. Following CT angiography for potential thrombolysis, aneurysmal formation was discovered proximal to the filling defect within mid-SMA. Blood cultures drawn at presentation grew Serratia marcescens. The patient was treated with appropriate antibiotic, and recommended indefinite anticoagulation. The patient was then recommended to follow up with vascular surgery within two weeks for repeat abdominal CT angiogram.

Mycotic Pulmonary Artery Aneurysm Mimicking a Rasmussen Aneurysm

BACKGROUND

Mycotic aneurysms arising from the pulmonary arteries are rare; only a few cases have been reported. Staphylococcus and Streptococcus species are the most common causative pathogens. Mycotic aneurysms are seldom clinically apparent unless as a sequela of adverse procedural complications. They carry high morbidity and mortality if not treated expeditiously.

CASE REPORT

We present the case of a 37-year-old male with bacteremia and bronchopneumonia associated with a pulmonary artery mycotic aneurysm. The case was confounded by clinical features mimicking a Rasmussen aneurysm. We discuss distinctive imaging features, disease mechanism, typical presentation, and management.

CONCLUSION

While mycotic aneurysms are uncommon, certain clinical scenarios warrant consideration of the diagnosis, such as a history of intravenous drug use, bacterial endocarditis, and immunocompromise. Rapid identification is critical to prevent life-threatening complications such as vessel rupture. Computed tomography allows for an accurate and timely diagnosis, and interventional embolization is a fast, minimally invasive curative treatment. Given similar risk factors and presentation, a mycotic aneurysm can be indistinguishable from a Rasmussen aneurysm; therefore, appropriate precautions should be taken while adequate microbiologic assessment is performed.